SCHEMBL10113291

SCHEMBL10113291

CC(C)(C)S(=O)(=O)NC1CCC(C(=O)Nc2cccc(CC(=O)O)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
NPY5R Q15761 1/20 0.48
NR1H4 Q96RI1 1/20 0.47
GAA P10253 2/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
GLA P06280 1/20 0.44
KMT2A Q03164 2/20 0.44
ACKR3 P25106 6/20 0.44
MAPT P10636 3/20 0.43
TP53 P04637 1/20 0.43
MEN1 O00255 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
SELP P16109 1/20 0.41
SELE P16581 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13203824 1.00 SMN1; SMN2 (0.50) SMN1; SMN2NPY5RNR1H4GAAUSP2
SCHEMBL10113283 0.90 SMN1; SMN2 (0.48) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL13203822 0.90 SMN1; SMN2 (0.48) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10133142 0.89 SMN1; SMN2 (0.65) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10133141 0.87 SMN1; SMN2 (0.50) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10114078 0.85 GRIA2 (0.50) SMN1; SMN2NR1H4GAAUSP2LMNA
SCHEMBL10114293 0.84 GLA (0.62) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10133376 0.84 GLA (0.62) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL10113273 0.83 NPY5R (0.53) SMN1; SMN2NPY5RGAAUSP2LMNA
SCHEMBL13203717 0.83 NPY5R (0.53) SMN1; SMN2NPY5RGAAUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885NPY5R 1/4885NR1H4 311/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885NPY5R 1/4885NR1H4 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.